

Application No. 10/777,792
Amendment dated June 2, 2006
Reply to the Restriction Requirement of March 2, 2006

REMARKS

After entry of this amendment, claims 119-143 are pending, claims 1-118 having been canceled and claims 119-143 having been added. Support for new independent claims 119 and 131 is provided at, *e.g.*, paragraph [0077] and paragraph [0126] of the amended specification. Support for new claims 120 and 132 is provided at, *e.g.*, paragraph [0014] of the specification. Support for new claims 121-124 and 134-137 is provided at, *e.g.*, paragraph [0157] of the specification. Support for new claims 125-127 and 138-140 is provided at, *e.g.*, paragraph [0129] of the specification. Support for new claims 128-130 and 141-143 is provided at, *e.g.*, paragraph [0130] of the specification. Support for new claim 133 is provided at, *e.g.*, paragraphs [0016], [0162], [0163] and [0164] of the specification. Thus, the new claims contain no new matter. Cancellations of the claims are made to remove non-elected subject matter. Applicants reserve the right to pursue the non-elected subject matter in one or more divisional applications.

In the specification, support for the amendment to paragraph [0126] is found at, *e.g.*, page 5, lines 3-5 and original claim 48 of U.S. Patent Application No. 09/201,430, issued as U.S. Patent No. 6,787,523, which is incorporated by reference in the instant specification.

RESPONSE TO RESTRICTION REQUIREMENT


In response to the Examiner's requirement, Applicants elect, without traverse, the claims of Group I, namely, original claims 69-78 and 102-103, which are drawn to a chimeric peptide comprising amyloid beta (A β) peptide and a T helper cell epitope. Applicants have canceled original claims 69-78 and 102-103 and have presented new claims 119-143. The new claims are directed to a pharmaceutical composition comprising A β 1-7 linked to CRM197.

Application No. 10/777,792
Amendment dated June 2, 2006
Reply to the Restriction Requirement of March 2, 2006

The Examiner has required Applicants to elect a single disclosed species for prosecution, namely, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:49, or SEQ ID NO:50. In light of the cancellation of claims 69-78 and 102-103, the election of a single species of the above-identified sequences is rendered moot. Applicants wish to draw the Examiner's attention that the new claims recite a single sequence, namely, A β 1-7.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-625-8100.

Respectfully submitted,



Rosemarie L. Celli
Registration No. 42,397

SUGHRUE MION, PLLC
Telephone: (650) 625-8100
Facsimile: (650) 625-8110

MOUNTAIN VIEW OFFICE

60032

CUSTOMER NUMBER

Date: June 2, 2006